Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Breast Cancer ResearchOpen Access

18FFDG PET/CT imaging of the metabolic response in advanced breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMarcin KubeczkoFOFrancisco P. M. OliveiraCCCláudia S. Constantino

Discussion

Loading...

Member takes

Overview

Cohort study reveals that metabolic tumor reduction on FDG-PET/CT predicts longer progression-free survival in advanced breast cancer, highlighting PET imaging as a valuable prognostic tool.

Key Points

  • To evaluate the prognostic value of metabolic response assessed by [18F]FDG-PET/CT in patients with advanced HR+/HER2-negative breast cancer undergoing treatment with CDK4/6 inhibitors.
  • Analyzed 97 patients (median age 61 years, IQR 53–72) with advanced HR+/HER2-negative breast cancer treated with CDK4/6 inhibitors (72% in the first-line setting) who received baseline and follow-up [18F]FDG-PET/CT scans.
  • Assessed maximum standardized uptake value at response assessment (SUVas) and percentage change in SUVmax from baseline (ΔSUVmax) as prognostic indicators for progression-free survival (PFS) and overall survival (OS) over a median follow-up of 27.5 months.
  • Median progression-free survival was 33.1 months, with a 2-year rate of 65.6% [95% CI: 54.8–75.4%], while 3-year overall survival reached 91.7% [95% CI: 80.6–96.6%] across 8 total death events.
  • Patients had a median ΔSUVmax decrease of 57% (IQR 33–73%), with greater ΔSUVmax reduction independently predicting longer progression-free survival in multivariable analysis (p = 0.003).

Cite This Study

Kubeczko et al. (2026) studied this question.

synapsesocial.com/papers/6aabb8495f706d05830e7f46https://doi.org/10.1186/s13058-026-02390-w
View Full Paper
Ask AI
Bookmark
Share